Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril/valsartan)

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril/valsartan)

Jul 07, 2015
Source URL: https://qa1.novartis.us/news/media-releases/novartis-new-heart-failure-medicine-lcz696-approved-fda-reduce-risk-cardiovascular-death-and-heart-failure-hospitalization-now-called-entrestotm-sacubitrilvalsartan-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-new-heart-failure-medicine-lcz696-approved-fda-reduce-risk-cardiovascular-death-and-heart-failure-hospitalization-now-called-entrestotm-sacubitrilvalsartan-0